Sarcoidosis is a granulomatous disease with an incidence of up to 18 in 100,000 in some populations. Symptoms range from asymptomatic benign lesions to organ failure, with up to 90% of patients presenting with lung involvement. Sarcoidosis is often a diagnosis of exclusion: inflammation, lymphadenopathy, and sterile granulomata without an identifiable cause. Granuloma formation occurs in primary immunodeficiencies, but the full landscape of these deficiencies and their association with sarcoid is not fully understood.
We looked retrospectively at patients initially diagnosed with sarcoidosis referred to the National Institutes of Health (NIH). Many people had refractory inflammation or had a diagnosis of sarcoidosis in the setting of other immune dysfunction such as common variable immunodeficiency (CVID). Within this group of 37 patients with completed whole-genome or whole-exome sequencing, 22 had pathogenic variants, likely pathogenic variants, or variants of unknown significance in relevant candidate genes including SP110, GATA2, NFKBIA, NFKB1, IRF8, CTLA-4, NCF1, SLC26A9, RFX5, MEFV, GFI1, PLCG2, STAT1, BACH2, IKZF3, JAK1, ADCY10, and STXBP2.
This study highlights the diseases often gathered under the diagnosis “sarcoid”. Prior studies have highlighted immune dysregulation within multiple pathways, including the interferon-gamma (IFN-γ) response pathway (GATA2, STAT1, NFKBIA, and IRF8), Th17.1 signaling (STAT1 and IRF8), and inflammasome response (IRF8, MEFV, and PLCG2), as being important in granuloma formation. Numerous mutations within this cohort have previously been associated with common immunodeficiencies (RFX5, NFKBIA, SP110, and IKZF3) or predominant antibody deficiencies (NFKB1). This cohort also showed defects of phagocyte number or function (GFI1, NCF1, and GATA2). Within this study, two variants were identified that are not associated with immunodeficiencies, including SLC26A9, an ion transporter for chloride previously identified in atypical cystic fibrosis, and ADCY10, a catalyst for the formation of cAMP. Though it is possible that some of these variants may not be causal or even relevant to the formation of granulomas, this cohort shows how some patients presenting with lymphadenopathy and sterile granulomata in various organs were identified to have Mendelian traits underlying their diagnoses of sarcoidosis.
Subject ID . | Genetic Defect Identified . | Allele Frequency gnomAD v4.1.0 . | Classification (ClinVar) . | Zygosity . | CADD Score . | Inheritance Pattern . | Organ Involvement . | Infection History . |
---|---|---|---|---|---|---|---|---|
1 | NFKBIA (IkBa) (c.691G>T, p.Asp231Tyr) | 4.7e-5 | VUS | Het | 27.3 | AD | CNS, Exocrine, Cutaneous | NTM, EBV |
2 | CTLA4 (c.567+5G>C) | 0 | Pathogenic | Het | 26 | AD | Ocular, LN, Cutaneous, Pulmonary | |
3 | No defect identified | Ocular, Cutaneous, Pulmonary | EBV | |||||
4 | NCF1 (p47phox Deficient CGD) (c.75_76del, p.Tyr26fs) | 8.5e-4 | Pathologic | Homo | 35 | AR | Pulmonary, Exocrine, LN | S. capitis |
5 | No defect identified | Cutaneous | Sphingomonas paucimobilis | |||||
6 | No defect identified | Pulmonary | M. avium | |||||
8 | No defect identified | Pulmonary, Neuro, LN | JCV | |||||
9 | No defect identified | Pulmonary | disseminated M. tilbergii | |||||
11 | NCF1 (p47phox Deficient CGD) (c.75_76del, p.Tyr26fs) | 8.5e-4 | Pathologic | Homo | 38 | AR | Pulmonary | |
12 | NCF1 (p47phox Deficient CGD) (c.75_76del, p.Tyr26fs) | 8.5e-4 | Pathologic | Homo | 38 | AR | MSK, Ocular, Splenic | A. fumigatus |
14 | 1q41 222762100-224070013 | Het | Hepatic, Pulmonary | S. pneumo | ||||
1.308 Mb-1.636 Mb Loss | ||||||||
IFIH1 | ||||||||
NOD2 | ||||||||
LRBA | ||||||||
FAT4 | ||||||||
KMT2D | ||||||||
15 | SP110 (c.1428_1429del, p.Tyr476Ter) | 1.8e-6 | Not Reported | Het | 34 | AR | Cutaneous | M. chelonae |
16 | SLC26A9 (c.1459G>A, p.Ala487Thr) | 6.9e-5 | Not Reported | Het | 20.8 | Pulmonary | MAC | |
17 | GATA2 (c.1021_1024dup, p.Ala342GlyfsTer43) | 0 | Pathologic | Het | NA | AD | Pulmonary | |
18 | No defect identified | Pulmonary, Cutaneous | ||||||
19 | IRF8 (c. 536C>T, p.Ala179Val) | 6.5e-6 | VUS | Het | 17.54 | AR/AD | Neuro | MAC |
20 | No defect identified | Pulmonary, GI | MAC | |||||
23 | GATA2 (c.1021_1024dup, p.Ala342GlyTer43) | 0 | Pathogenic | Het | NA | AD | BM | |
25 | STXBP2 (c.1001 C>T, p.Pro334Leu) | 4e-5 | Likely pathogenic | Homo | 29.9 | AR | Hepatic | |
26 | No defect identified | Pulmonary | ||||||
27 | No defect identified | Pulmonary | ||||||
28 | NFKB1 (c.1513A>C, p.Lys505Gln) | 6.85e-7 | VUS | Het | 26.2 | AD | Pulmonary, Cardiac | |
29 | RFX5 (c.353+2T>G) | 1.8e-4 | Likely pathogenic | Het | 33 | AR | Pulmonary, Cutaneous | |
30 | IKZF3 (c.244G>A, p.Glu82Lys) | 1.4e-4 | VUS | Het | 23.6 | AD | Hepatic, Ocular | Recurrent Pneumonia |
31 | No defect identified | Pulmonary | EBV | |||||
32 | No defect identified | Cardiac | ||||||
33 | No defect identified | Neuro | VZV | |||||
34 | MEFV (c.289C>A, p.Gln97Lys) | 9.43e-5 | VUS | Het | 9.8 | AD/AR | Pulmonary, Hepatic | |
35 | GFI1 (c.200G>A, p.Arg67Lys) | 3.4e-5 | VUS | Het | 21.2 | AR | Pulmonary | Aspergillus, pneumocystis |
36 | PLCG2 (c.2931C>G, p.Tyr977Ter) | 6.19e-7 | VUS | Het | 38 | AD | Pulmonary, Splenic, Cutaneous | Recurrent sinusitis |
37 | STAT1 (c.736G>A, p.Ala246Thr) | 0 | VUS | Het | 24 | AD | Pulmonary | Histoplasmosis |
38 | BACH2 (c.2327 C>T, p.Pro776Leu) | 1.8e-5 | VUS | Het | 16.9 | AD | Pulmonary | |
39 | No defect identified | Pulmonary | ||||||
40 | ADCY10 (c.4477del, p.Leu1493SerfsTer24) | 3e-4 | Pathogenic | Het | 33 | AD | Pulmonary | |
41 | No defect identified | Pulmonary | ||||||
42 | No defect identified | Cardiac | ||||||
43 | JAK1 (c.1078C>T, p.Arg360Trp) | 5.9e-5 | VUS | Het | 25.1 | AD/AR | T1DM, Pulmonary, Ocular | Histoplasmosis |
Subject ID . | Genetic Defect Identified . | Allele Frequency gnomAD v4.1.0 . | Classification (ClinVar) . | Zygosity . | CADD Score . | Inheritance Pattern . | Organ Involvement . | Infection History . |
---|---|---|---|---|---|---|---|---|
1 | NFKBIA (IkBa) (c.691G>T, p.Asp231Tyr) | 4.7e-5 | VUS | Het | 27.3 | AD | CNS, Exocrine, Cutaneous | NTM, EBV |
2 | CTLA4 (c.567+5G>C) | 0 | Pathogenic | Het | 26 | AD | Ocular, LN, Cutaneous, Pulmonary | |
3 | No defect identified | Ocular, Cutaneous, Pulmonary | EBV | |||||
4 | NCF1 (p47phox Deficient CGD) (c.75_76del, p.Tyr26fs) | 8.5e-4 | Pathologic | Homo | 35 | AR | Pulmonary, Exocrine, LN | S. capitis |
5 | No defect identified | Cutaneous | Sphingomonas paucimobilis | |||||
6 | No defect identified | Pulmonary | M. avium | |||||
8 | No defect identified | Pulmonary, Neuro, LN | JCV | |||||
9 | No defect identified | Pulmonary | disseminated M. tilbergii | |||||
11 | NCF1 (p47phox Deficient CGD) (c.75_76del, p.Tyr26fs) | 8.5e-4 | Pathologic | Homo | 38 | AR | Pulmonary | |
12 | NCF1 (p47phox Deficient CGD) (c.75_76del, p.Tyr26fs) | 8.5e-4 | Pathologic | Homo | 38 | AR | MSK, Ocular, Splenic | A. fumigatus |
14 | 1q41 222762100-224070013 | Het | Hepatic, Pulmonary | S. pneumo | ||||
1.308 Mb-1.636 Mb Loss | ||||||||
IFIH1 | ||||||||
NOD2 | ||||||||
LRBA | ||||||||
FAT4 | ||||||||
KMT2D | ||||||||
15 | SP110 (c.1428_1429del, p.Tyr476Ter) | 1.8e-6 | Not Reported | Het | 34 | AR | Cutaneous | M. chelonae |
16 | SLC26A9 (c.1459G>A, p.Ala487Thr) | 6.9e-5 | Not Reported | Het | 20.8 | Pulmonary | MAC | |
17 | GATA2 (c.1021_1024dup, p.Ala342GlyfsTer43) | 0 | Pathologic | Het | NA | AD | Pulmonary | |
18 | No defect identified | Pulmonary, Cutaneous | ||||||
19 | IRF8 (c. 536C>T, p.Ala179Val) | 6.5e-6 | VUS | Het | 17.54 | AR/AD | Neuro | MAC |
20 | No defect identified | Pulmonary, GI | MAC | |||||
23 | GATA2 (c.1021_1024dup, p.Ala342GlyTer43) | 0 | Pathogenic | Het | NA | AD | BM | |
25 | STXBP2 (c.1001 C>T, p.Pro334Leu) | 4e-5 | Likely pathogenic | Homo | 29.9 | AR | Hepatic | |
26 | No defect identified | Pulmonary | ||||||
27 | No defect identified | Pulmonary | ||||||
28 | NFKB1 (c.1513A>C, p.Lys505Gln) | 6.85e-7 | VUS | Het | 26.2 | AD | Pulmonary, Cardiac | |
29 | RFX5 (c.353+2T>G) | 1.8e-4 | Likely pathogenic | Het | 33 | AR | Pulmonary, Cutaneous | |
30 | IKZF3 (c.244G>A, p.Glu82Lys) | 1.4e-4 | VUS | Het | 23.6 | AD | Hepatic, Ocular | Recurrent Pneumonia |
31 | No defect identified | Pulmonary | EBV | |||||
32 | No defect identified | Cardiac | ||||||
33 | No defect identified | Neuro | VZV | |||||
34 | MEFV (c.289C>A, p.Gln97Lys) | 9.43e-5 | VUS | Het | 9.8 | AD/AR | Pulmonary, Hepatic | |
35 | GFI1 (c.200G>A, p.Arg67Lys) | 3.4e-5 | VUS | Het | 21.2 | AR | Pulmonary | Aspergillus, pneumocystis |
36 | PLCG2 (c.2931C>G, p.Tyr977Ter) | 6.19e-7 | VUS | Het | 38 | AD | Pulmonary, Splenic, Cutaneous | Recurrent sinusitis |
37 | STAT1 (c.736G>A, p.Ala246Thr) | 0 | VUS | Het | 24 | AD | Pulmonary | Histoplasmosis |
38 | BACH2 (c.2327 C>T, p.Pro776Leu) | 1.8e-5 | VUS | Het | 16.9 | AD | Pulmonary | |
39 | No defect identified | Pulmonary | ||||||
40 | ADCY10 (c.4477del, p.Leu1493SerfsTer24) | 3e-4 | Pathogenic | Het | 33 | AD | Pulmonary | |
41 | No defect identified | Pulmonary | ||||||
42 | No defect identified | Cardiac | ||||||
43 | JAK1 (c.1078C>T, p.Arg360Trp) | 5.9e-5 | VUS | Het | 25.1 | AD/AR | T1DM, Pulmonary, Ocular | Histoplasmosis |